Imatinib mesylate (STI571) in patients with chronic myeloid leukemia in chronic phase previously submitted to autologous stem cell transplantation.

被引：0
|
作者：
Cervantes, F
Hernández-Boluda, JC
Odriozola, J
Camós, M
Villalón, L
Martínez-Climent, JA
del Campo, R
García-Conde, J
Montserrat, E
机构：
[1] IDIBAPS, Hosp Clin, Dept Hematol, Barcelona, Spain
[2] Hosp Clin, Dept Hematol & Oncol, Valencia, Spain
[3] Hosp Ramon y Cajal, Hematol Serv, E-28034 Madrid, Spain
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4818
引用
收藏
页码：318B / 318B
页数：1
相关论文
共 50 条
  • [31] Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia
    McNamara, C
    Grigg, A
    Szer, J
    Roberts, A
    Campbell, L
    Hoyt, R
    Lynch, K
    Juneja, S
    CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (02): : 119 - 125
  • [32] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [33] Imatinib mesylate for the treatment of relapse of chronic myeloid leukaemia after allogeneic stem cell transplantation.
    Olavarria, E
    Fischer, T
    Ottmann, O
    Clark, R
    Bandini, G
    Byrne, J
    Lipton, J
    Niederwieser, D
    Goldman, J
    BLOOD, 2002, 100 (11) : 329B - 329B
  • [34] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    Kiguchi, Toru
    Tauchi, Tetsuzo
    Ito, Yoshikazu
    Miyazawa, Keisuke
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
  • [35] Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase.
    Mauro, MJ
    Deininger, MW
    O'Dwyer, ME
    Maziarz, RT
    Walker, T
    Kurilik, G
    Druker, BJ
    BLOOD, 2002, 100 (11) : 781A - 781A
  • [36] Skin reactions to imatinib mesylate (STI-571) in patients with chronic myeloid leukemia (CML): Clinical features and histopathology.
    Stone, R
    Galinsky, I
    Haynes, H
    Soiffer, R
    Alyea, E
    Neuberg, D
    Tawa, M
    Antin, J
    Resta, D
    Granter, S
    DeAngelo, D
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [37] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    Fischer, T
    Reifenrath, C
    Hess, GR
    Corsetti, MT
    Kreil, S
    Beck, J
    Meinhardt, P
    Beltrami, G
    Schuch, B
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    Carella, A
    Huber, C
    LEUKEMIA, 2002, 16 (07) : 1220 - 1228
  • [38] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    T Fischer
    C Reifenrath
    GR Hess
    MT Corsetti
    S Kreil
    J Beck
    P Meinhardt
    G Beltrami
    B Schuch
    H Gschaidmeier
    R Hehlmann
    A Hochhaus
    A Carella
    C Huber
    Leukemia, 2002, 16 : 1220 - 1228
  • [39] STI 571 combined with hematopoetic stem cells transplantation for chronic myeloid leukemia.
    Meng, FY
    Sun, J
    Liu, QF
    Xu, D
    Wei, YQ
    Zhang, Y
    Jiang, QL
    BLOOD, 2005, 106 (11) : 293B - 293B
  • [40] Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy -: a fluorescence in-situ hybridization study
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Ollig, E
    Schmitt-Graeff, A
    Staib, P
    Griesshammer, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (08) : 1627 - 1631
12345